The development of tactics to effectively manage various bone illnesses, including bone abnormalities, bone infections, fractures, osteoarthritis, osteoporosis, and malignancies, has become a significant public health concern for achieving optimal bone repair outcomes. Conventionally, bisphosphonates and monoclonal antibody medications have shown partial clinical efficacy in bone regeneration. However, issues such as medication resistance, life-threatening off-target side effects, and poor bioavailability continue to affect the majority of patients. Additionally, surgical interventions like subchondral bone microfracture, lavage, debridement, and shaving are primarily effective for minor bone defects. For severe bone defects, the gold standard treatment involves implanting autologous or allogeneic bone grafts. Nevertheless, these grafts come with challenges, such as donor site complications, immune rejection, infections, and limited tissue availability.

中文翻译：

---

超越药物递送：金属-有机框架衍生的纳米系统在复杂病理微环境下的骨再生


制定有效管理各种骨骼疾病的策略，包括骨骼异常、骨骼感染、骨折、骨关节炎、骨质疏松症和恶性肿瘤，已成为实现最佳骨骼修复结果的重要公共卫生问题。传统上，双膦酸盐和单克隆抗体药物在骨再生方面显示出部分临床疗效。然而，耐药性、危及生命的脱靶副作用和生物利用度差等问题继续影响着大多数患者。此外，软骨下骨微骨折、灌洗、清创和剃须等手术干预主要对轻微的骨缺损有效。对于严重的骨缺损，金标准治疗包括植入自体或同种异体骨移植物。然而，这些移植物也带来了挑战，例如供体部位并发症、免疫排斥、感染和组织可用性有限。